Skip to main content
WW logo

WW · Ww International, Inc.

Track WW — free
$6.97 -1.00 (-12.55%) At close · Nov 20
Market Cap
$69.69M
Shares
10.00M
Volume · Nov 20 474.38K Avg daily vol (3M) 278.22K

Price & Indicators

 

Key stats

Close
$6.97
Fri 20 Nov
Open
$7.77
Fri 20 Nov
Average volume, 30 days
293K
shares a session
Short interest
2.0M
20.5% of shares · 17.3 days to cover
Day range
$6.83$7.81
Open $7.77 Close $6.97
52-week closing range
$6.97$34.43
Close $6.97 79.8% under the high
Short volume, last session
58%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jun 2025 to Nov 2026

Up next

Mar 15, 2027 Est · unconfirmed · in 16 wks

Latest documents

2026
Nov 17
Current report 8-K
WW Plans Up to $10 Million Discounted Term Loan Prepayment Solicitation

WW International announced it intends to use up to $10 million in cash to prepay part of its term loan at a discount through a voluntary solicitation of offers from term loan lenders. The solicitation is expected to commence on Tuesday, November 17, 2026 and close on Friday, November 20, 2026.

Regulation FD disclosure
2 source passages
intends to utilize up to $10 million in cash to prepay a portion of its outstanding term loan at a discount through a voluntary solicitation of offers from its term loan lenders The solicitation is expected to commence on Tuesday, November 17, 2026 and close on Friday, November 20, 2026. Open the document at this passage
Nov 5
Earnings call
Revenue falls as clinical subscriptions and EBITDA rise

Weight Watchers reported third quarter 2026 revenue of $152.9 million, down 11%, while clinical subscription revenue increased 48% to $38 million and adjusted EBITDA increased 21% to $51.7 million. Full-year revenue guidance narrowed to $625 million to $630 million.

5 source passages
Thank you for joining us today for Weight Watchers' third quarter 2026 earnings conference call. third quarter revenue was $152.9 million, down 11% Clinical subscription revenue increased 48% to $38 million Adjusted EBITDA increased 21% to $51.7 million We now expect revenue of $625 million to $630 million Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue fell 11.2% as net income reached $15.1 million

WW International, Inc. reported revenue of $152.9 million for the three months ended September 30, 2026, down 11.2% from $172.1 million, while net income reached $15.1 million.

Revenue $152.9M Net income $15.11M Diluted EPS $1.51
Read from the MD&A section
3 source passages
WW International, Inc. is a Virginia corporation with its principal executive offices in New York, New York. Revenue was $152.9 million for the three months ended September 30, 2026 (Successor), a decrease of $19.2 million, or 11.2%, compared to revenue for the three months ended September 30, 2025 (Successor) of $172.1 million. | | (In millions, except per share amounts and percentages) | | | --- | --- | --- | | | Successor | | | | Three Months Ended | Three Months Ended | | | September 30, 2026 | September 30, 2025 | | Net income (loss) | 15.1 | (57.5) | *All values are in US Dollars.* Open the document at this passage
Nov 5
Current report 8-K
Clinical revenue grows 48% as net income turns positive

WW International reported Q3 revenue of $152.9 million, down 11% year-over-year, while Clinical Subscription Revenue grew 48% to $38.0 million. Net income reached $15.1 million and Adjusted EBITDA was $51.7 million.

Financial results Read from the first part of this long document
3 source passages
WW INTERNATIONAL, INC. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the third quarter of fiscal 2026 ended September 30, 2026 Q3 Revenue was $152.9 million, down 11% year-over-year. Clinical Subscription Revenue grew 48% year-over-year to $38.0 million and represented 25% of total Revenue, up from 15% in Q3 2025. Net Income for Q3 was $15.1 million, compared to a Net Loss of $57.5 million in Q3 2025. Q3 Adjusted EBITDA^1^ increased 21% year-over-year to $51.7 million from $42.8 million in Q3 2025, reflecting continued expense discipline and lower marketing relative to Q3 2025, which included investment to support a product launch. Open the document at this passage
Sep 21
Current report 8-K/A Events of Sep 9
Director or officer change, or executive pay

WW International, Inc. and Stephen J. Bye agreed his appointment as President, Chief Executive Officer and director will take effect October 1, 2026. Felicia DellaFortuna and Jonathan Volkmann will leave the Interim Office of the Chief Executive upon its dissolution but retain their officer roles.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$100.03M
Trailing 12 months
Revenue growth YoY
-17.0%
Year over year
Operating margin
-30.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$297.53M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.3%
Year over year · more shares
Price change (1Y)
-67.0%
Trailing year
Short interest
20.5%
Latest settlement · 17.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Weight Watchers reported positive net income, higher adjusted EBITDA, positive operating cash flow, reduced debt, clinical and CorePlus subscriber growth, and narrowed full-year guidance. Revenue and behavioral subscribers declined, clinical subscribers fell sequentially, adjusted gross margin was lower year over year, Q1 awareness gains did not persist, and marketing spending is expected to increase in Q4.

Bullish
  • + Clinical subscription revenue grew 48% year over year to $38 million and represented approximately 25% of total revenue. new
  • + CorePlus enrollment in the GLP-1 Success Program more than doubled since January. new
  • + Operating cash flow was positive at $32.3 million and total debt has been reduced by more than 70% since the financial reorganization. new
  • + Full-year revenue and adjusted EBITDA guidance ranges were narrowed, with the lower ends raised. new
  • + Adjusted EBITDA increased 21% year over year to $51.7 million and adjusted EBITDA margin improved to 33.8% from 24.9%. new
Bearish
  • − Clinical subscribers declined sequentially from 197,000 at the end of June to 174,000, and moderate sequential declines are expected in Q4. new
  • − Awareness gains from the concentrated Q1 clinical marketing investment did not carry through the year as anticipated. new
  • − Marketing spending is expected to increase modestly in Q4, and full-year marketing expense as a percentage of revenue is expected to rise versus 2025. new
  • − Third-quarter revenue declined 11% year over year to $152.9 million. new
  • − Behavioral subscription revenue declined 22% year over year to $113.9 million, primarily reflecting the smaller CORE subscriber base. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −54%
below
Price vs 50-day avg −49%
below
RSI (14) 26
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −48%
trailing
6-month return −56%
trailing
YTD return −76%
this year
Relative strength −47%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $14 › 200d $15 — 200d above 50d
Institutional flow Accumulating
+15% holders QoQ · +21 funds added
Insider flow Accumulating
Net +$192.8K over 90 days · 0% sells
Short interest Rising
20.46% of shares out · ▲ +9.1% MoM · 17.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
91 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Fair
Revenue growth +12%
Y/Y
Gross margin 41%
contracting
EPS growth −197%
Y/Y
Free cash flow $-17.6M
Buyback $208.9M
remaining
Balance sheet $1.4B
net debt
Quant / Vol
risk profile
Very High
Volatility 98%
annualized · 1-yr
Max drawdown −80%
past year
ATR 19.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 8
Latest guidance · from the Earnings Call filed Nov 5, 2026
full-year 2026
Revenue Maintained $625M – $630M
Aug 5, 2026 $620M – $635M changed to Nov 5, 2026 $625M – $630M
Adjusted EBITDA Non-GAAP Raised $110M – $115M
Aug 5, 2026 $105M – $115M changed to Nov 5, 2026 $110M – $115M
Adjusted growth margin Non-GAAP 74%
Clinical subscription revenues as a percentage of full-year reve 25%
Projected interest costs Maintained $45M – $50M
Aug 5, 2026 $45M – $50M changed to Nov 5, 2026 $45M – $50M
2026
Gross margin 74%
MedPlus share of revenue 25%
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Clinical subscription revenue as a percent of total revenue · 2026 25% – 30%
Cash taxes · 2026 $5M – $10M
Guided vs delivered · last 8 settled
Revenue full year fiscal 2024
guided at least $770M
$785.92M In line
Revenues Full Year Fiscal 2023
guided $910M – $930M
$889.55M Miss −3.3%
Revenues Q1 2023
guided $235M
$241.9M Beat +2.9%
Revenues Full Year Fiscal 2022
guided $1.04B
$1.04B Miss −0.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−54% Bearish
Price vs 50-day avg
−49% Bearish
RSI (14)
26 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $14 › 200d $15 — 200d above 50d
Institutional flow Accumulating
+15% holders QoQ · +21 funds added
Insider flow Accumulating
Net +$192.8K over 90 days · 0% sells
Short interest Rising
20.46% of shares out · ▲ +9.1% MoM · 17.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
91 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7 Now $7 · 0% Range high $34
vs 200-day avg -54% vs 50-day avg -49%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $39.8M Three Months Ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
EBITDA 41.2M (non-GAAP)
+0M Franchise rights acquired impairments
+0M Reorganization items, net
-4.6M Gain on extinguishment of debt
+0M Transaction costs
-0.2M Restructuring charges
+3.8M Executive related one-time costs
-0.4M Other
= Adjusted EBITDA 39.8M
Adjusted EBITDA Margin non-GAAP 24.5% Q2 2026 —
Adjusted Gross Margin non-GAAP 73.6% Q2 2026 —
Behavioral Subscription Revenue (Constant Currency) $120.7M Q2 2026 filing —
Core+ End of Period Subscribers 541K Q2 2026 —
End of Period Behavioral Subscribers 2.29M Six Months Ended June 30, 2026 —
End of Period Clinical Subscribers 197K Six Months Ended June 30, 2026 —
End of Period Subscribers 2.49M Six Months Ended June 30, 2026 —
Incoming Behavioral Subscribers 2.63M Six Months Ended June 30, 2026 —
Incoming Clinical Subscribers 130K Six Months Ended June 30, 2026 —
Incoming Subscribers 2.76M Six Months Ended June 30, 2026 —
Marketing expense as a percentage of Revenue 29.5% Q2 2026 —
Monthly Behavioral Subscription Revenue Per Average Subscriber $16.91 Six Months Ended June 30, 2026 —
Monthly Behavioral Subscription Revenue Per Average Subscriber (Constant Currency) $16.92 Q2 2026 filing —
Monthly Clinical Subscription Revenue Per Average Subscriber $75.13 Six Months Ended June 30, 2026 —
Monthly Clinical Subscription Revenue Per Average Subscriber (Constant Currency) $67.55 Q2 2026 filing —
Monthly Subscription Revenue Per Average Subscriber $20.76 Six Months Ended June 30, 2026 —
Monthly Subscription Revenue Per Average Subscriber (ARPU) growth 10.2% Q2 2026 —
Monthly Subscription Revenue Per Average Subscriber (Constant Currency) $20.8 Q2 2026 filing —
Monthly Subscription Revenues Per Average Subscriber $20.9 Three Months Ended June 30, 2026 —
Total End of Period Subscribers 2.5M Q2 2026 —
Total Subscription Revenue (Constant Currency) $160.6M Q2 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
WW
Ww International, Inc.
this stock
$69.69M -76.1% +12.2% — 20.5%
HCA
HCA Healthcare, Inc.
$99.34B +1.9% +7.1% 15.8 2.3%
FSNUY
Fresenius SE & Co. KGaA
$31.59B -2.2% — — 0.0%
THC
Tenet Healthcare Corp
$20.95B +32.4% +0.9% 7.6 2.2%
EHC
Encompass Health Corp
$13.11B +25.9% +10.5% 20.9 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
91
% held
69.9%
Net QoQ
-800.8K sh
Top holder
COOPER CREEK PARTNERS MAN…
Held Float
View
Held by Funds
Fund positions
60
View
Short & Settlement
Short Interest Rising
Shares short
2.0M
Days to cover
17.3d
Change
+171.5K sh
View
Short Volume
Short vol %
58%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
323
Value
$4.3K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
35.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$192.8K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Congressional Trades Buy
Member
Thomas R Carper
Amount
$1.0K–$15.0K
Traded
Aug 11, 2021
View
Financials
Financials
Revenue (FY)
$785.9M
Net income (FY)
$1.1B
EPS diluted
$-4.34
View
Buybacks
Authorized
$250.0M
Remaining
$208.9M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 17, 2026
This year
24

WW International announced it intends to use up to $10 million in cash to prepay part of its term loan at a discount through a voluntary solicitation of offers from term loan lenders. The solicitation is expected to commence on Tuesday, November 17, 2026 and close on Friday, November 20, 2026.

View
Proposed Sales
Value
$335.1K
Shares
45.9K
Filed
Nov 30, 2023
View
Exempt Offerings
Offering
$34.7M
Filed
Apr 14, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Weight Watchers Announces Discoun…
Published
Nov 17, 2026
View

Performance

5D 20D 120D MTD YTD
WW -32.8% -48.3% -56.4% -53.2% -76.1%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -24.2% -39.0% -47.2% -44.5% -77.3%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$250.00M
Spent (derived)
$41.10M
Remaining
$208.90M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 105319 CUSIP 98262P200 13F (30d) 103 filings 87 filers Visit website Investor relations